Table 1.
In vitro activity of tetracycline and third-generation tetracycline-class drugs against select gram-positive, gram-negative, and anaerobic pathogens [35,103,104].
| Organism (n) | Tetracycline |
Tigecycline |
Omadacycline |
Eravacycline |
||||
|---|---|---|---|---|---|---|---|---|
| MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | MIC90 (mg/L) | %S* | |
| Bacteroides fragilis | –a | –a | 4 | –a | –a | –a | 1 | –a |
| Enterococcus faecalis | >16 | 24.8 | 0.12 | 99.1 | 0.25 | 98.2 | 0.06 | 94.5 |
| Vancomycin resistant | >16 | 17.0 | 0.12 | 100 | 0.12 | –a | 0.12 | 89.8 |
| Escherichia coli | >16 | 69.3 | 0.25 | 100 | 2 | –a | 0.25 | 99.2 |
| ESBL phenotype | >8 | 88.1 | 0.25 | 100 | 2 | –a | –a | –a |
| Haemophilus influenzae | 1 | 99.7 | 0.25 | 90.5 | 1 | 99.7 | 0.25 | –a |
| Klebsiella pneumoniae | >16 | 77.0 | 1 | 96.8 | 4 | 91.0 | 1 | 85.7 |
| ESBL phenotype | >16 | 39.8 | 2 | 92.0 | 16 | 73.9 | –a | –a |
| Staphylococcus aureus | 0.25 | 98.3 | 0.12 | 100 | 0.25 | 97.8 | 0.12 | 84.5 |
| Methicillin resistant | 0.12 | 99.7 | 0.25 | 95.2 | 0.5 | 97.2 | 0.12 | 80.8 |
| Streptococcus pneumoniae | >4a | 79.7a | 0.12 | 86.9 | 0.12 | 97.6 | 0.015 | a |
| Penicillin resistant, oral | >4a | 48.5a | 0.12 | 84.8 | 0.12 | 93.9 | 0.016 | –a |
| Macrolide resistant | >4a | 61.0a | 0.12 | 84.9 | 0.12 | 95.1 | 0.016 | –a |
| Tetracycline resistant | >4a | 0 | 0.12 | 82.4 | 0.12 | 91.2 | 0.016 | –a |
| Streptococcus pyogenes | >4 | 73.9 | 0.12 | 98.6 | 0.12 | –a | 0.03 | 100 |
*
Susceptibility data are derived from FDA identified breakpoints. Criteria as published by CLSI.
CLSI: Clinical and Laboratory Standards Institute; ESBL: extended-spectrum β-lactamase; FDA: Food and Drug Administration: MIC: minimum inhibitory concentration.
a
Breakpoints unavailable.